Hyaluronic Acid: Common Difficulties Encountered by Buyers During Procurement & HiSiaddi’s Solutions

As an innovative foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of Hyaluronic Acid from multiple well-known original manufacturers. As a research and development-oriented foreign trade enterprise, HiSiaddi will systematically sort out common challenges faced by B-end buyers sourcing Hyaluronic Acid in China and propose targeted solutions from a professional perspective.

If you require more professional and in-depth analysis regarding Hyaluronic Acid procurement, please contact HiSiaddi customer service.

I. High-End Cosmetic, Oral Health & Medical Aesthetic Pharmaceutical Enterprises (EU & US Markets)

(High-purity HA powder, oral capsules, aesthetic injectables, ophthalmic dressings)

(I) Pain Points

1. Molecular weight drift and excessive protein impurities: Crude fermentation products carry high residual protein; high-molecular-weight HA degrades into low-molecular-weight fractions. Medical aesthetic and oral applications impose strict heteroprotein limits; excess protein triggers sensitization, and actual molecular weight inconsistent with labeling violates labeling regulations in the EU and US.

2. Excessive endotoxins disqualify products for pharmaceutical use: Injectables and eye drops require ultra-low endotoxin levels; insufficient purification leads to full-batch rejection.

3. Excess residual fermentation solvents trigger FDA sampling recalls.

4. Strong hygroscopicity causes high moisture, caking and sticking during tableting: Moisture-induced stickiness results in cracked tablets and agglomerated capsules during automated production.

5. Molecular chain breakage and sharp viscosity drop under high-temperature processing: Molecular degradation during granulation or sterilization renders finished products unqualified due to substandard viscosity.

6. Non-compliant heavy metal and microorganism levels block market access for medical and oral grades.

(II) Solutions

1. Closed fermentation, multi-stage membrane separation and ethanol precipitation refining to lock molecular weight ranges precisely; heteroprotein residues far below regulatory limits.

2. Multi-stage ultrafiltration for depyrogenation to meet endotoxin standards for medical aesthetic and ophthalmic pharmaceutical applications.

3. Segmented vacuum solvent removal and repeated pure water rinsing to reduce solvent residues to less than 50% of regulatory thresholds.

4. Low-temperature vacuum freeze-drying to control moisture ≤0.3%, delivering free-flowing powder resistant to moisture absorption for smooth tableting without sticking.

5. Molecular stabilization modification for powder; molecular weight degradation limited to <3% under short-term processing at 90℃.

6. Class 10,000 sterile subpackaging and heavy metal chelation purification, meeting food, cosmetic and pharmaceutical grade standards simultaneously.

II. European & American Skincare & Functional Food Manufacturers

(Skincare serum powder, oral chewable tablets, solid beverages, gummy candies)

(I) Pain Points

1. Slow dissolution and agglomeration of high-molecular-weight HA in cold water, forming flocs and turbid solutions.

2. Powder bridging causes feeding blockages, inconsistent loss-in-weight batching and batch-to-batch viscosity variance.

3. Uneven particle size creates gritty, sticky residues in chewable products.

4. Rapid moisture absorption and clumping in open workshop environments; regrinding degraded the molecular structure.

(II) Solutions

1. Ultrafine grinding and hydrophilic modification for instant cold-water dissolution; solutions remain clear without flocculation after 72 hours of refrigeration at 0℃.

2. Formulation with food-grade flow aids to limit batching error within 1% and eliminate feeding blockages.

3. Precision airflow classification for uniform particle size, delivering smooth mouthfeel without gritty residues in oral products.

4. Moisture-resistant coating and high-barrier sealed bags to prevent caking under standard workshop humidity.

III. Japanese & South Korean Cosmetic, Oral Wellness & Cosmeceutical Raw Material Buyers

(Japanese beauty oral liquids, joint care tablets, serum stock solution raw materials)

(I) Pain Points

1. Heavy metal and inorganic arsenic levels approaching regulatory limits, failing inspections by the Ministry of Health, Labour and Welfare.

2. Missing local food/cosmetic raw material filings prohibit labeling moisturizing or joint care efficacy, limiting product premium potential.

3. Stringent long-term aqueous solution stability requirements; batches are rejected for minor precipitation or turbidity.

4. Batch-to-batch molecular weight fluctuation complicates formulation adjustment for brand owners.

(II) Solutions

1. Multi-stage ion exchange and deep chelation purification to reduce heavy metal levels to below 40% of Japanese/South Korean regulatory limits.

2. Support for Japanese raw material filing agency services and provision of full Japanese-language compliance documentation to enable legal efficacy labeling and boost product premiums.

3. Deep impurity removal and solution stabilization systems to maintain clear stock solutions for 30 days at ambient temperature without precipitation.

4. Fully automated closed-loop production to limit molecular weight and purity fluctuation to ≤0.4%.

IV. Affordable Daily Chemical & General Nutraceutical Manufacturers in India & Southeast Asia

(Affordable skincare raw materials, mass-market joint health tablets, cost-oriented procurement)

(I) Pain Points

1. Low-cost adulteration with glucose, maltodextrin or inferior low-molecular-weight HA to counterfeit high-purity raw materials, resulting in insufficient active ingredients and impaired moisturizing performance.

2. Unstandardized molecular weight and moisture content force frequent formulation adjustments, reducing production efficiency by over 20% and raising scrap rates.

3. Rapid moisture absorption, caking and hydrolytic deterioration under hot-humid storage conditions lead to full-batch scrapping.

4. Missing COAs, MSDS and HALAL certificates create high risks of customs detention during filing; lack of storage guidance elevates abnormal loss rates.

(II) Solutions

1. Economical grade without starch or sugar adulteration, stable HA indicators with prices 22%–27% lower than high-purity grades.

2. Fixed molecular weight, moisture and solubility parameters to lock customer dosing ratios.

3. Double-layer moisture-proof packaging (PE inner bag + woven sack) plus anti-caking additives to resist moisture absorption and hydrolysis for 3 months under 45℃ high-humidity conditions.

4. Batch-specific COAs, MSDS and HALAL certificates provided for customs clearance filing support.

5. Simplified moisture-proof storage guidance to reduce abnormal material losses.

V. Overseas Raw Material Repackagers & Cosmetic/Health Product Traders

(Repackaged small-volume skincare products, compound nutritional raw materials)

(I) Pain Points

1. Sugar adulteration and counterfeit low-grade HA with falsely labeled molecular weight trigger compensation claims after sales.

2. Thin, non-moisture-proof packaging causes caking and molecular degradation during marine transit, leading to rejected shipments.

3. Open storage induces moisture deterioration, resulting in rejection by high-end brands; incomplete qualifications bar access to premium supply chains.

4. Moisture ingress during open repackaging creates inconsistent quality in small finished packs.

(II) Solutions

1. Direct supply from original manufacturers with full COAs including molecular weight, protein and endotoxin test data; global third-party re-inspection supported with zero adulteration guarantee.

2. Heavy-duty cardboard drums with double-layer high-barrier vacuum aluminum foil inner bags for compression, water and moisture resistance during marine shipping.

3. Vacuum-sealed packaging plus storage guidance; physicochemical indicators remain stable for 12 months under cool storage at 25℃.

4. One-stop full set of compliance documents including FDA, REACH, HALAL, KOSHER and Japanese/South Korean filing certifications.

5. Closed moisture-proof repackaging protocols to maintain uniform quality across bulk and small packs for consistent end-market repeat purchases.

If you require more professional and in-depth analysis regarding Hyaluronic Acid procurement, please contact HiSiaddi customer service.

Lead time

The monthly inventory volume of Hyaluronic acid is 10 tons, with appropriate adjustments upwards or downwards in response to peak and off-peak seasons.

HiSiaddi safeguards the supply stability of Hyaluronic acid through the following measures:

1. Supply of one mainstream Hyaluronic acid model by 3 premium factories

(1) Performance evaluation and screening of Hyaluronic acid brand factories based on on-time delivery rate, batch pass rate, timeliness of risk alerts, and completeness of documentation to assess their supply stability.

(2) For each mainstream model or major grade of Hyaluronic acid, secure 1 primary high-quality brand manufacturer and 2 backup high-quality manufacturers.

(3) Each factory operates independent production lines in separate production zones to prevent production halts caused by major unforeseen incidents such as environmental production suspensions and power outages.

2. Technological transformation partnerships and long-term sales binding for Hyaluronic acid

Through long-term cooperation with brand manufacturers via technology commercialization and authorized distribution channels, HiSiaddi can effectively strengthen supervision over the production processes of brand manufacturers, optimize full-process traceability management, improve batch stability control, and further reinforce real-time monitoring of the supply stability of Hyaluronic acid products.

Long-term Annual Framework Supply Guarantee Agreement. HiSiaddi signs 12-month long-term agreements with leading manufacturers. The agreements specify the minimum guaranteed supply volume, maximum price hike range, and priority production scheduling rights during peak seasons. It is stipulated that manufacturers shall issue a 30-day prior written notice if production is suspended due to environmental rectification or equipment maintenance, and backup manufacturers will be activated to replenish goods accordingly.

3. 4 warehouses and 10 peak & off-peak demand forecasting

We have 4 warehouses, which are jointly operated and managed with suppliers to store hot-selling products.The four warehouses are located at Qingdao Port in North China, Ningbo Port in East China, Shenzhen Port in South China, and Zhengzhou, China’s inland logistics hub. This setup guarantees sufficient supply and timely shipment of Hyaluronic acid during peak seasons.

HiSiaddi issues a rolling demand forecast covering the subsequent three months on the 25th of each month, allowing manufacturers to reserve production capacity in accordance with the forecast. Any new urgent orders from overseas clients will be prioritized to draw on inventories or production capacity from backup manufacturers.

4. Multi-channel logistics to resolve vessel congestion and inspection delays for Hyaluronic acid sea and land shipments

Unstable logistics for Hyaluronic acid will extend delivery lead times. HiSiaddi has established alternative arrangements covering multiple freight forwarders, ports and transportation solutions:

(1) Binding of multiple professional chemical freight forwarders for Hyaluronic acid

Each product is assigned 2 to 3 freight forwarders with hazardous chemical/food transport qualifications affiliated with different shipping lines. Alternative sailing schedules can be switched to immediately in case of space shortages or customs inspections on a single shipping route.

(2) Backup transportation solutions for Hyaluronic acid

Ocean freight serves as the standard mode; air freight and rail freight are reserved as alternatives for urgent orders. Long-term agreements for temperature-controlled containers are signed for temperature-sensitive and perishable food additives to secure shipping space.

(3) Visual tracking and digital early warning for Hyaluronic acid

Freight forwarders synchronize daily updates on container loading, customs declaration, vessel loading and port arrival milestones. If customs inspection occurs, replenishment from backup inventory will be initiated immediately to shorten client waiting periods.

Full-chain digital early warning automatically monitors four categories of risks:

• Factory side: Expiring supplier environmental assessment certificates, renewal of production permits, scheduled major equipment overhauls, and notifications of price hikes for upstream raw materials;

• Inventory side: Inventory falling below safety thresholds, excessive inventory age, and batches failing quality inspection;

• Logistics side: Shipping line space shortages, strikes at destination ports, and updates to customs policies;

• Overseas side: Revisions to additive regulations and adjustments to import restriction lists in target countries.

Early warning notifications are automatically pushed to procurement and business leads, allowing backup suppliers or inventory contingency plans to be activated in advance.

Hyaluronic Acid: What Qualifications & Certifications Have China’s Leading Brands Obtained? What Is Their Market Feedback?

As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade, HiSiaddi has established a "1+2+3+4=1" service system, offering access to raw materials directly from multiple well-known original manufacturers of Hyaluronic Acid.

As a R&D-focused foreign trade service provider, HiSiaddi does not only promote a single factory’s own products. We objectively analyze multiple highly competitive Chinese export brands of Hyaluronic Acid and share their certification credentials and market feedback to help buyers make efficient, secure purchasing decisions.

If you require more authentic, objective introductions to multiple leading Chinese Hyaluronic Acid brands, please contact HiSiaddi customer service.

I. Bloomage Biotech: Global HA Leader & Benchmark for Full-Range High-End Products

(I) Core Export Grades Covering All Segments (Medical Aesthetics / Pharmaceuticals / Skincare / Food)

1. Nano HA® (5–10 kDa, enzymatic oligomer): Flagship skincare-grade material, the world’s first enzymatically digested oligomeric Hyaluronic Acid.

2. Hymagic® (<5 kDa, ultra-active small molecule): High-activity repair variant for sensitive skin.

3. Haplex® Plus (Food-Grade): For oral anti-aging and joint care, high-purity fermented material.

4. Hyatrue® HA-EP-S3.0 (Sterile Pharmaceutical-Grade): For orthopedic and ophthalmic injections with low endotoxin levels.

5. Twinha® (Cross-Linked Medical Aesthetic-Grade): Long-lasting contouring filler with high viscoelasticity.

(II) Global Market Feedback: Top Market Share in High-End Segments with Over 90% Repeat Purchase Rate

· European & American Skincare Market: Nano HA® achieves 36.2% transdermal absorption within 1 hour and 91.7% absorption after 8 hours. Long-term supplier to L’Oréal, SkinCeuticals and other top brands; awarded "Top Penetration Skincare Raw Material in Europe 2025".

· Medical Aesthetic End Market: Twinha® earns a 92% recommendation rate from overseas plastic surgeons for its strong support, low displacement and natural shaping. North American medical aesthetic clinics posted a 93% repeat purchase rate in 2025.

· Food-Grade Segment: Haplex® Plus exported to 40+ countries, with overseas sales of 42.8 tons in 2025 accounting for 47.7% of China’s total food-grade HA exports. Rated "Most Stable Oral HA Raw Material" by North American health supplement brands.

· Client Reputation: Global customers consistently praise its precise molecular weight, stable batch consistency and impurity levels below 0.1%, with an international customer satisfaction score of 97.3% in 2025.

(III) Global Authoritative Recognition: Most Comprehensive Certifications with Global Patented Technology Backing

· Certification Credentials: FDA GRAS (Food-Grade), EU Novel Food, CE (Medical Aesthetics / Pharmaceuticals), GMP, ISO 9001/13485, China National Gold Patent Award.

· Technological Recognition: Enzymatic digestion technology holds patents across the US, EU and Japan; Frost & Sullivan recognized it as "World’s Top HA Enterprise for Technological Innovation".

· Industry Awards: 2026 PCHi Fountain Awards, first Chinese raw material selected for NYSCC Top Innovation Showcase, nominee for In-cosmetic Global Sustainability Award.

· Academic Endorsement: Designated HA supplier for stem cell research at top institutions including the University of Tokyo and Harvard University.

II. Focusfreda: World’s Second-Largest Exporter & Leader in Cosmetic-Grade HA

(I) Core Export Grades (Cost-Effective Benchmark Focused on Cosmetic & Food-Grade)

1. Acetylated Sodium Hyaluronate (AcHA): Lipophilic HA, core raw material for high-end skincare.

2. Lysine Hyaluronate (LyHA): Collagen-stimulating repair variant for anti-aging applications.

3. Food-Grade HA Powder (FCH-95): 95% purity for health supplements and functional food.

4. Conventional Skincare-Grade HA (Full range 50–2000 kDa): Basic moisturizing raw material in universal demand from global mass-market brands.

(II) Global Market Feedback: Core Supplier to L’Oréal & Shiseido, Industry Benchmark for Cost Performance

· European & American Beauty Conglomerates: 65% of export volume supplies L’Oréal, Shiseido and Johnson & Johnson; named "Best HA Raw Material Supplier of 2025" by L’Oréal with zero quality complaints for 8 consecutive years.

· Emerging Markets: Top choice for Southeast Asian and Middle Eastern skincare brands, with 2025 export volume of USD 312 million accounting for 25.1% of China’s total HA exports. Customers comment its quality matches international standards at prices 20%–30% lower.

· Food-Grade Growth: Food-grade HA exports surged 41% year-on-year in 2025, recognized as a Clean Beauty Recommended Raw Material by the European Health Supplement Association.

· Stability Reputation: Overseas clients report molecular weight batch deviation <5%, stable pH values and zero microbial exceedances across batches.

(III) Global Authoritative Recognition: Comprehensive Compliance Certifications with Global Clean Beauty Credentials

· Certification Credentials: EU ECOCERT Organic Certification, FDA Cosmetic Registration, ISO 9001, GMP, Halal Certification.

· Industry Recognition: Awarded "Top Quality Supplier of the Year 2025" by the Global Cosmetic Raw Materials Association (CTFA); AcHA named "2025 European Innovative Skincare Raw Material".

· Compliance Endorsement: China’s first enterprise with food-grade HA export filing and EU Novel Food certification (jointly with Bloomage Biotech).

III. Fufeng Biotech: Fermentation Technology Benchmark & Specialist in High-Purity Pharmaceutical-Grade HA

(I) Core Export Grades (Focused on High-Molecular-Weight Pharmaceutical & Industrial-Grade with Significant Cost Advantages)

1. High-Molecular-Weight HA (1500–3000 kDa, Pharmaceutical-Grade): For orthopedic joint injections and ophthalmic viscoelastic agents with ≥98.5% purity.

2. Low-Endotoxin HA (LF-HA): For sterile injectable formulations with endotoxin levels <0.05EU/mg.

3. Industrial-Grade HA (90%–95% purity): Basic raw material for facial masks and body care products, ultimate cost-performance option.

(II) Global Market Feedback: Preferred Supplier for Orthopedic & Ophthalmic Pharmaceutical Clients with Standout Purity Reputation

· European & American Pharmaceutical Market: Supplied over 50 tons of orthopedic HA to Aikon Medical, Double Medical and other manufacturers in 2025. Overseas pharmaceutical firms praise its ≥98.5% purity, endotoxin levels far below EP standards and consistent stability.

· Price Competitiveness: Pharmaceutical-grade HA priced 35%–40% lower than European and American suppliers, with 2025 export volume of USD 158 million and an 89% repeat purchase rate among overseas pharmaceutical clients.

· Industrial-Grade Reputation: Essential raw material for mass-market skincare brands in Southeast Asia and South America; clients highlight fast dissolution, stable moisturization and odor-free formulation.

(III) Global Authoritative Recognition: Robust Pharmaceutical-Grade Credentials with Internationally Certified Fermentation Technology

· Certification Credentials: European EP Pharmacopoeia Certification, US USP Certification, GMP, ISO 13485, FDA DMF Filing.

· Technological Recognition: Industry-leading fermentation yield (12g/L); awarded "Best Fermentation Technology Enterprise 2025" by the International Fermentation Engineering Association.

· Client Endorsement: Designated supplier to Merck Germany and Johnson & Johnson Pharmaceuticals US, passing FDA on-site audits for 5 consecutive years.

IV. Shandong Freda: Pioneer of Medical Aesthetic End Products & Ophthalmic-Grade HA Specialist

(I) Core Export Grades (Deep Expertise in Ophthalmic-Grade & Cross-Linked Medical Aesthetic-Grade)

1. Low-Endotoxin Ophthalmic HA (OP-HA): For artificial tears and cataract surgery viscoelastic agents with endotoxin levels <0.03EU/mg.

2. Cross-Linked Medical Aesthetic HA (FD-CL): For superficial & mid-layer fillers and hydrafacial injections with 8%–15% cross-linking degree.

3. Medical-Grade HA Solution (1%): For post-surgical anti-adhesion and wound repair.

(II) Global Market Feedback: Top Global Market Share in Ophthalmic Medical-Grade HA with Steady Medical Aesthetic End-Product Reputation

· Global Ophthalmic Market: Exported 32 tons of ophthalmic HA raw materials in 2025, capturing 38% of the global ophthalmic HA raw material market. Long-term supplier to Alcon and Bausch + Lomb, commended for exceptional biocompatibility and post-surgical inflammation rates <0.5%.

· Medical Aesthetic End Market: Its Runbaiyan hydrafacial product is China’s only hydrafacial with NMPA Class III certification, exported to Southeast Asia and Eastern Europe with an 85% repeat purchase rate among overseas medical aesthetic clinics in 2025.

· Brand Reputation: Overseas clients recognize its stringent medical-grade standards, complete clinical data and exceptional safety profiles.

(III) Global Authoritative Recognition: Top-Tier Ophthalmic Credentials with Globally Certified Medical Aesthetic Compliance

· Certification Credentials: CE (Ophthalmology / Medical Aesthetics), ISO 13485, GMP, NMPA Class III Product Certification, EU REACH Registration.

· Industry Recognition: Awarded "Top Ophthalmic HA Supplier of the Year 2025" by the International Ophthalmology Association; cross-linking technology holds EU patents.

· Clinical Endorsement: Provides 5+ years of complete ophthalmic and medical aesthetic clinical data recognized by the FDA.

V. Amhwa Biotech: High-End Medical-Grade Emerging Player & Leader in Low-Impurity Technology

(I) Core Export Grades (Differentiated Sterile Medical-Grade & Ultra-High-Purity Skincare-Grade Technology)

1. EvoHA® Sodium Hyaluronate (Sterile-Grade): For orthopedic joint cavity viscoelastic supplementation, manufactured under proprietary Waterble® purification technology.

2. Ultra-High-Purity HA (≥99.5%, Skincare-Grade): For high-end anti-aging and post-procedure repair with impurity levels <0.05%.

3. Low-Molecular-Weight HA (10–50 kDa, Transdermal-Grade): For serums and ampoules with strong penetration capacity.

(II) Global Market Feedback: Favored by High-End Medical Clients with Standout Low-Impurity Brand Reputation

· European & American High-End Medical Aesthetics: EvoHA® sourced by Swiss and German medical aesthetic clinics, praised for ≥99.5% purity, sensitization rates <0.01% and consistent degradation cycles.

· High-End Skincare Lines: Supplies ultra-high-purity HA to niche luxury European skincare brands, with 2025 export volume of USD 107 million. Clients highlight non-irritating formulations and potent repair efficacy suitable for sensitive skin.

· Technological Reputation: Overseas clients recognize its industry-leading Waterble® purification technology and consistent batch uniformity.

(III) Global Authoritative Recognition: Patented Purification Technology with Complete Medical-Grade Credentials

· Certification Credentials: GMP, WC-GMP, ISO 9001/13485, European EP Pharmacopoeia Certification, API Registration Number (Y20200000498).

· Technological Recognition: Proprietary Waterble® purification technology holds international patents; Frost & Sullivan named it "Most Promising HA Purification Technology 2025".

· Compliance Endorsement: Endotoxin levels far below national standards, with EU CE certification and TÜV Rheinland Germany audit clearance.

VI. Quick Reference Comparison of Core Information for the Five Leading Brands

表格

If you require more authentic, objective introductions to multiple leading Chinese Hyaluronic Acid brands, please contact HiSiaddi customer service.

Hyaluronic Acid: How Are the Production Processes, Supply Stability and Key Technical Indicators of China’s Five Leading Brands?

As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade, HiSiaddi has established a "1+2+3+4=1" service system, offering access to raw materials directly from multiple well-known original manufacturers of Hyaluronic Acid.

As a R&D-focused foreign trade service provider, HiSiaddi does not only promote a single factory’s own products. We objectively analyze multiple highly competitive Chinese export brands of Hyaluronic Acid and share their production processes, supply stability and core technical indicators, as well as the downstream impacts of these key factors, to help buyers make efficient, secure purchasing decisions.

If you require more authentic, objective introductions to multiple leading Chinese Hyaluronic Acid brands, please contact HiSiaddi customer service.

I. Bloomage Biotech: Full Self-Developed Industrial Chain, World’s Largest HA Production Capacity

(I) Production Process: Full-Stack Synthetic Biology + Enzymatic Digestion + Cross-Linking Technology Covering All Segments

1. Core Fermentation Process (Self-Mutagenized High-Yield Strains + High-Density Fermentation) Adopts self-mutagenized high-yield Streptococcus zooepidemicus strains, paired with 500m³ stainless steel fermentation tanks. Carbon and nitrogen sources include glucose and yeast extract, with precise control at 37°C, pH 7.0±0.2 and dissolved oxygen ≥30%. Fermentation yield reaches 12–14g/L (industry average: 6–8g/L) with a 48–52 hour cycle, 20% shorter than industry standards.

2. Purification Process (Three-Stage Membrane Filtration + Activated Carbon Decontamination + Aseptic Lyophilization) Fermentation broth → microfiltration (0.22μm sterilization) → ultrafiltration (100kDa interception for protein removal) → nanofiltration (desalination & concentration) → activated carbon (decolorization & pyrogen removal) → aseptic lyophilization (for medical aesthetic/pharmaceutical-grade) / spray drying (for skincare/food-grade). Impurity removal rate ≥99.9%, endotoxin controllable to <0.05EU/mg.

3. Differentiated Finishing Technology (Dual Enzymatic Digestion & Cross-Linking Platforms)

1. Enzymatic Digestion: Self-developed targeted enzymatic digestion technology precisely cuts HA into 5–10 kDa (Nano HA) and <5 kDa (Hymagic®) oligomers with molecular weight distribution index PDI ≤1.15.

2. Cross-Linking: Self-developed BDDE cross-linking process with controllable cross-linking degrees of 10%–30%, delivering degradation cycles of 6–18 months for long-lasting medical aesthetic fillers.

(II) Supply Stability: Global Largest Production Base with Redundant Multi-Site Risk Mitigation

· Production Capacity Scale: Three manufacturing bases in Jinan, Tianjin and Dongying with total annual capacity of 1,200 tons (35% of global output): 300 tons pharmaceutical-grade, 200 tons medical aesthetic-grade, 500 tons skincare-grade, 200 tons food-grade.

· Delivery Capability: Standard orders (100kg–5 tons) delivered within 7–15 days; urgent orders scheduled within 3–5 days. Flexible small-batch production starting at 10kg for custom brand formulations.

· Risk Mitigation: Dual strain backup, 3-month strategic stock of glucose raw materials, dual logistics channels (sea freight + air freight). 98.7% on-time delivery rate in 2025 with a 0.3% supply disruption rate.

(III) Key Technical Indicators: Industry-Leading Strict Full-Spectrum Standards

· Purity: ≥99.5% for pharmaceutical/medical aesthetic-grade, ≥99.0% for skincare/food-grade.

· Molecular Weight: Fully customizable range from 5 Da to 6000 kDa with PDI ≤1.15 (≤1.10 for medical aesthetic-grade).

· Endotoxin: <0.05EU/mg for pharmaceutical-grade, <0.03EU/mg for ophthalmic-grade.

· Microorganisms: Total colony count <10CFU/g, pathogenic bacteria undetected.

· Heavy Metals: Lead <0.1mg/kg, Arsenic <0.05mg/kg, compliant with EP/USP pharmacopoeia standards.

(IV) Impacts on Downstream Buyers: Consistent Quality, Strong Customization Capabilities & High Product Premiums

· Medical Aesthetic Institutions: Batch-consistent cross-linked HA delivers stable shaping effects with complication rates <0.01%, supporting premium end pricing of USD 1,500–2,000 per syringe.

· Skincare Brands: Nano HA oligomers achieve 36.2% transdermal absorption with quantifiable efficacy, ideal for high-end anti-aging lines with 30%–50% product premiums.

· Pharmaceutical Companies: 100% endotoxin compliance eliminates secondary purification requirements for injectable production and reduces compliance risks.

· Health Supplement Manufacturers: FDA GRAS-certified food-grade HA accelerates market filing timelines by 6–8 months.

II. Focusfreda: Fermentation & Molecular Modification Technology, Cost-Performance King of Cosmetic-Grade HA

(I) Production Process: High-Efficiency Fermentation + Chemical Modification Focused on Skincare & Food-Grade

1. Fermentation Process (Optimized Strains + Low-Cost Carbon Sources) Adopts mutagenized Lactobacillus plantarum strains paired with 300m³ fermentation tanks. Corn starch hydrolysate replaces glucose to cut raw material costs by 15%, controlled at 35°C, pH 6.8±0.2 with fermentation yield of 10–11g/L over a 50–55 hour cycle.

2. Purification Process (Two-Stage Membrane Filtration + Spray Drying) Microfiltration (0.45μm) → ultrafiltration (200kDa) → concentration → spray drying (180°C inlet air). Purity ≥99.0% with endotoxin <0.1EU/mg, optimized for skincare and food-grade applications.

3. Core Modification Technology (Acetylation / Lysination) Self-developed AcHA (acetylated HA) and LyHA (lysine HA) technologies introduce lipophilic groups onto HA molecular chains, doubling transdermal absorption capacity and boosting collagen synthesis by 30% for premium anti-aging skincare formulations.

(II) Supply Stability: Large-Scale Dual Manufacturing Bases Optimized for Mass Market Demand

· Production Capacity Scale: Two bases in Shandong and Jiangxi with total annual capacity of 800 tons: 500 tons skincare-grade, 200 tons food-grade, 100 tons pharmaceutical-grade.

· Delivery Capability: Standard orders delivered within 5–10 days; bulk orders above 1 ton qualify for volume discounts. Low minimum order quantity of 5kg ideal for small-to-medium brands.

· Risk Mitigation: 1-year fixed-price long-term supply contracts with corn raw material suppliers; 97.5% on-time delivery rate in 2025 with price volatility controlled below 5%.

(III) Key Technical Indicators: Skincare-Grade Benchmark Optimized for Cost Performance

· Purity: ≥99.0% for skincare/food-grade, ≥98.5% for pharmaceutical-grade.

· Molecular Weight: Full range 50–2000 kDa with PDI ≤1.20.

· Endotoxin: <0.1EU/mg for skincare-grade, <0.5EU/mg for food-grade.

· Modification Degree: Acetylation substitution ratio 0.8–1.2mol/mol with stable lipophilic performance.

(IV) Impacts on Downstream Buyers: Low Costs, Wide Compatibility, Top Cost-Performance Option

· Skincare Brands: AcHA/LyHA deliver efficacy matching international premium brands at prices 20%–30% lower, ideal for mid-tier premium lines of L’Oréal, Shiseido and similar brands.

· Health Supplement Manufacturers: Price advantages for food-grade HA support affordable joint care and skin anti-aging product lines.

· Small & Medium Buyers: Low minimum order quantities and fast delivery enable small-batch trial production to reduce inventory risks.

III. Fufeng Biotech: Fermentation + Membrane-Chromatography Coupling Purification, High-Purity Pharmaceutical-Grade Specialist

(I) Production Process: High-Yield Fermentation + Deep Purification Focused on Orthopedic & Ophthalmic Pharmaceutical-Grade

1. Fermentation Process (Genetically Engineered Strains + High-Density Cultivation) Adopts recombinant Streptococcus strains paired with 500m³ fermentation tanks using high-nutrient carbon/nitrogen sources (glucose + peptone). Controlled at 38°C, pH 7.2±0.1 and dissolved oxygen ≥40% with fermentation yield of 11–12g/L over a 45–48 hour cycle for low impurity profiles.

2. Core Purification Process (Membrane Separation-Chromatography Coupling + Lyophilization) Microfiltration → ultrafiltration → ion exchange chromatography (protein/pyrogen removal) → gel filtration chromatography (molecular weight grading) → aseptic lyophilization. Endotoxin controlled below 0.01EU/mg with purity ≥98.5%.

3. High-Molecular-Weight Enrichment Technology Self-developed molecular weight grading technology concentrates 1500–3000 kDa high-molecular-weight HA with high viscoelasticity tailored for orthopedic joint injections.

(II) Supply Stability: Dedicated Pharmaceutical-Grade Production Capacity with Long-Term Key Client Contracts

· Production Capacity Scale: Single manufacturing base in Binzhou, Shandong with total annual capacity of 600 tons: 250 tons pharmaceutical-grade (150 tons orthopedic, 100 tons ophthalmic), 350 tons industrial-grade.

· Delivery Capability: Pharmaceutical-grade orders require 15–20 days lead time for sterility validation; industrial-grade delivered within 5–7 days. Long-term contract clients (e.g., Merck Germany) receive priority scheduling.

· Risk Mitigation: Dedicated pharmaceutical-grade production lines (no cross-production with industrial-grade materials) with full batch traceability. 98.2% on-time delivery rate for pharmaceutical-grade products in 2025 with zero quality complaints.

(III) Key Technical Indicators: Industry-Leading Pharmaceutical-Grade Standards with Exceptional Endotoxin Control

· Purity: ≥98.5% for pharmaceutical-grade, ≥95.0% for industrial-grade.

· Molecular Weight: Orthopedic-grade 1500–3000 kDa (PDI ≤1.25); Ophthalmic-grade 800–1500 kDa (PDI ≤1.30).

· Endotoxin: <0.01EU/mg for orthopedic-grade, <0.005EU/mg for ophthalmic-grade (surpassing EP pharmacopoeia standards).

· Viscoelasticity: High-molecular-weight HA storage modulus G’ ≥100Pa with joint cavity retention time ≥6 months.

(IV) Impacts on Downstream Buyers: Fully Compliant Pharmaceutical-Grade Raw Materials, Top Orthopedic Supplier Choice

· Orthopedic Pharmaceutical Manufacturers: Endotoxin compliance enables direct formulation into joint cavity injectables with clinical inflammation rates <0.5%, preferred by Aikon Medical, Double Medical and other industry leaders.

· Ophthalmic Pharmaceutical Manufacturers: Ultra-low-endotoxin HA delivers exceptional biocompatibility with minimal post-operative irritation for artificial tears and cataract surgery viscoelastic agents.

· Cost Advantages: Pharmaceutical-grade HA priced 35%–40% lower than European and American suppliers, drastically cutting raw material expenses for pharmaceutical firms.

IV. Shandong Freda: Full Self-Developed Industrial Chain, Dual Strengths in Ophthalmic-Grade & Mild Cross-Linked Medical Aesthetic-Grade HA

(I) Production Process: Traditional Fermentation + Precision Enzymatic Digestion + Mild Cross-Linking Deeply Optimized for Medical-Grade Applications

1. Fermentation Process (Classic Strains + Plant Peptone Nitrogen Sources) Adopts traditional Streptococcus zooepidemicus strains paired with 400m³ fermentation tanks using self-produced soybean hydrolysate plant peptone as nitrogen source. Controlled at 36°C, pH 7.0±0.2 with fermentation yield of 10–12g/L over a 50-hour cycle for superior biocompatibility.

2. Purification Process (Ultrafiltration + Activated Carbon + Aseptic Filtration) Microfiltration → ultrafiltration (150kDa) → activated carbon (pyrogen removal) → 0.22μm aseptic filtration → lyophilization. Ophthalmic-grade endotoxin <0.03EU/mg with purity ≥99.0%.

3. Cross-Linking Technology (Low-Sensitization Cross-Linking Agents) Self-developed FD-CL cross-linking technology (non-BDDE cross-linkers) delivers controllable cross-linking degrees of 8%–15% with sensitization rates <0.01%, optimized for superficial/mid-layer fillers and hydrafacial injections.

(II) Supply Stability: Global Ophthalmic-Grade Market Leader with Expanding Medical Aesthetic Capacity

· Production Capacity Scale: Single manufacturing base in Jinan, Shandong with total annual capacity of 500 tons: 150 tons ophthalmic-grade, 100 tons medical aesthetic-grade, 250 tons skincare-grade.

· Delivery Capability: Ophthalmic-grade orders require 20–25 days lead time with complete clinical data packages; medical aesthetic-grade delivered within 10–15 days. Long-term exclusive supplier to Alcon and Bausch + Lomb.

· Risk Mitigation: Dedicated ophthalmic-grade production lines with full clinical reports for every batch. 99.0% on-time delivery rate for ophthalmic-grade products in 2025, capturing 38% of the global ophthalmic HA raw material market.

(III) Key Technical Indicators: Gold-Standard Ophthalmic-Grade Specifications with Safety-First Medical Aesthetic-Grade Formulations

· Purity: ≥99.0% for ophthalmic-grade, ≥98.5% for medical aesthetic-grade.

· Molecular Weight: Ophthalmic-grade 800–1500 kDa (PDI ≤1.30); Medical Aesthetic-grade 500–1500 kDa (PDI ≤1.25).

· Endotoxin: <0.03EU/mg for ophthalmic-grade, <0.05EU/mg for medical aesthetic-grade.

· Cross-Linking Degree: 8%–15% for medical aesthetic-grade with degradation cycles of 6–12 months for natural contouring effects.

(IV) Impacts on Downstream Buyers: Dominant Ophthalmic Market Share, Preferred Safe Medical Aesthetic Raw Material

· Ophthalmic Pharmaceutical Manufacturers: Captures 38% of the global ophthalmic HA raw material market with 5+ years of complete clinical data, directly applicable to artificial tears and surgical viscoelastic agents for long-term supply to Alcon and Bausch + Lomb.

· Medical Aesthetic Institutions: Low-sensitization cross-linked HA minimizes complication risks, ideal for sensitive skin and superficial/mid-layer filler treatments targeting mid-tier medical aesthetic markets in Southeast Asia and Eastern Europe.

· Compliance Advantages: China’s only supplier of NMPA Class III certified hydrafacial raw materials with high overseas registration approval rates.

V. Amhwa Biotech: Compound Mutagenesis + Targeted Purification, Emerging Leader in Ultra-Low-Impurity High-End Medical-Grade HA

(I) Production Process: Compound Mutagenesis + ProEnzy Enzymatic Digestion + Waterble Purification, Benchmark for Minimal Impurity Profiles

1. Fermentation Process (Compound Mutagenesis Strains + High-Throughput Screening) Self-developed targeted compound mutagenesis technology screens high-yield mutant Lactobacillus plantarum strains paired with 300m³ fermentation tanks using glucose and yeast extract carbon/nitrogen sources. Controlled at 37°C, pH 7.1±0.1 with fermentation yield of 10–11g/L, offering stable genetic expression and minimal impurity generation.

2. Core Purification Process (Proprietary Waterble® Technology + Low-Temperature Lyophilization) Microfiltration → ultrafiltration → Waterble® targeted purification (protein/nucleic acid/pyrogen removal) → low-temperature lyophilization. Impurity levels <0.05% with purity ≥99.5% and endotoxin <0.02EU/mg.

3. Enzymatic Digestion Technology (Proprietary ProEnzy® Precision Digestion) Self-developed ProEnzy® enzymatic digestion technology precisely manufactures 10–50 kDa low-molecular-weight HA with enhanced penetration capacity for high-end anti-aging serums and post-procedure repair formulations.

(II) Supply Stability: Dedicated High-End Medical-Grade Capacity with Flexible Custom Delivery

· Production Capacity Scale: Single manufacturing base in Binzhou, Shandong with total annual capacity of 400 tons: 150 tons high-end medical-grade, 250 tons high-end skincare-grade.

· Delivery Capability: Customized orders delivered within 15–20 days with flexible small-batch production starting at 5kg, catering to Swiss/German medical aesthetic clinics and European luxury skincare brands.

· Risk Mitigation: Exclusive proprietary Waterble® purification technology creates strong technical barriers; 92% repeat purchase rate among high-end clients in 2025 with zero batch quality complaints.

(III) Key Technical Indicators: Industry-Leading Ultra-Low-Impurity High-End Medical-Grade Standards

· Purity: ≥99.5% for high-end medical/skincare-grade with impurity levels <0.05%.

· Molecular Weight: 10–50 kDa (low-molecular-weight) / 800–2000 kDa (high-molecular-weight) with PDI ≤1.18.

· Endotoxin: <0.02EU/mg, surpassing EP pharmacopoeia standards.

· Microorganisms: Sterile-grade (zero microbial detection) for post-procedure repair applications.

(IV) Impacts on Downstream Buyers: Ultra-Low-Impurity Safe Formulations for Premium Market Premiums

· High-End Medical Aesthetic Institutions: 99.5% purity with sensitization rates <0.01% ideal for delicate facial contouring and post-procedure repair, supporting end pricing above USD 2,000 per syringe.

· Luxury Skincare Brands: High-penetration low-molecular-weight HA delivers non-irritating formulations for sensitive skin and post-procedure repair lines with 40%–60% product premiums.

· Compliance Advantages: Proprietary Waterble® purification technology holds international patents with high registration approval rates across Europe and the US.

VI. Quick Reference Comparison of Core Dimensions for the Five Leading Brands

表格

If you require more authentic, objective introductions to multiple leading Chinese Hyaluronic Acid brands, please contact HiSiaddi customer service.

Hyaluronic Acid: Key Factors for Buyers to Consider When Purchasing Based on HiSiaddi’s Market Experience

As an innovative foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of Hyaluronic Acid from multiple well-known original manufacturers. As a research and development-oriented foreign trade enterprise, HiSiaddi will analyze key purchasing considerations and critical indicators from a professional perspective to ease procurement concerns.

If you require more professional and in-depth analysis regarding Hyaluronic Acid procurement, please contact HiSiaddi customer service.

I. Core Comprehensive Global Procurement Factors (Pre-Transaction Risk Control)

(I) Regulatory Compliance Verification for Target Markets

Classification: Cosmetic raw material, food additive, pharmaceutical excipient, medical raw material. Authorities worldwide impose strict controls on glucuronic acid content, protein residues, molecular weight distribution, ethanol residues, endotoxins, heavy metals and microorganisms.

· European Union: REACH registration, CPNP notification for cosmetic raw materials; edible HA complies with the EFSA approved additive list; pharmaceutical-grade HA follows EP Pharmacopoeia with stringent limits on heteroproteins and pyrogens.

· North America: FDA cosmetic raw material filing; oral hyaluronic acid regulated under cGMP as dietary ingredients; pharmaceutical excipients aligned with USP standards; ophthalmic dressings subject to pharmacopoeia specifications.

· Japan & South Korea: Separate filings for cosmetics, food and pharmaceuticals with the Ministry of Health, Labour and Welfare; strict limits on protein residues, microorganisms and molecular weight deviation.

· Southeast Asia, Middle East & South America: General daily chemical and food raw material standards. For re-export to EU, US, Japan or South Korea, batch-specific COAs, full third-party SGS test reports and traceability documents are mandatory. Customs authorities inspect MSDS and batch test certificates; shipments with excessive residues or incomplete qualifications will be detained and returned.

(II) Selection Matching Downstream Production Processes

Appearance: White or off-white fine powder, highly soluble in pure water, insoluble in alcohol and organic solvents.

1. Molecular weight and molecular weight distribution: High-molecular-weight HA delivers film-forming and moisturizing effects; low-molecular-weight HA enables transdermal absorption; ultra-low-molecular-weight HA is readily absorbed for oral use. Excessive molecular weight deviation impairs skin feel and efficacy of finished formulations.

2. Heteroprotein residues: Mandatory critical indicator for medical aesthetics and eye drop grades; excessive protein causes sensitization and eye irritation.

3. Moisture content and powder flowability: Affect automatic feeding and capsule filling; high moisture leads to moisture absorption and caking.

4. Acid, alkali and thermal stability: Stable under neutral conditions; molecular degradation and viscosity loss occur under strong acid/alkali environments or prolonged high-temperature sterilization.

5. Compatibility: Compatible with ectoin, arbutin, glutathione and plant extracts for skincare formulations. Avoid long-term coexistence with high-concentration strong acids or alkalis; conduct compatibility stability tests for new formulations in advance.

(III) Grade Classification & Selection Criteria

1. Medical injection & eye drop grade: Glucuronic acid ≥42.0%, protein <0.1%, low endotoxin, sterile; suitable for intra-articular injections, artificial tears and aesthetic injectables.

2. High-end medical cosmetic grade: Glucuronic acid ≥41.5%, protein <0.15%, available in multiple molecular weights; for serums, medical aesthetic masks and repair lotions/creams.

3. General daily chemical grade: Glucuronic acid ≥40.0%, compliant protein limits; for affordable wash care and body lotion raw materials.

4. Oral food grade: Compliant with food additive regulations of target countries, low/ultra-low molecular weight; for oral HA drinks, capsules and solid beverages.

(IV) Supplier Production Capacity & Supply Stability Assessment

Core production process: Streptococcus fermentation → fermentation broth sterilization → crude precipitation with ethanol → multi-stage membrane purification → alcohol removal → freeze drying / spray drying. Key control points: precise molecular weight regulation, heteroprotein removal, thorough organic solvent elimination and endotoxin management. Prioritize integrated manufacturers with self-owned fermentation and continuous purification lines; verify ISO22000, GMP and ISO13485 (medical device qualification). Large manufacturers feature stable molecular weight and minimal protein fluctuation, and support cross-border testing via SGS and Eurofins. Full-container, consolidated and small sample shipments are available with standard lead times of 7–10 days. Small manufacturers suffer insufficient purification, elevated protein levels and volatile molecular weight, disqualifying their products for export to pharmaceutical and high-end cosmetic markets.

(V) Cross-Border Packaging, Storage & Transportation Solutions

Physicochemical properties: Strong hygroscopicity; stable at room temperature and away from light; rapid caking upon exposure to moisture; non-hazardous chemical.

· Packaging: Standard 25kg barrels with double-layer vacuum aluminum foil inner bags and light-shielding cardboard drums; independent vacuum aluminum foil small packages for high-purity medical grade.

· Storage & transport conditions: Cool, shaded environment throughout the supply chain; warehouse temperature ≤30℃, relative humidity ≤60%.

· Prohibitions: No co-storage with water-containing, volatile, strong acid or alkali materials; implement first-in-first-out inventory management to prevent long-term stockpiling and moisture absorption.

(VI) Customized Supporting Services

Precise molecular weight customization (ultra-low / low / medium / high molecular weight), compound hyaluronic acid blends (HA + acetylated HA + cross-linked HA), sterile treatment, powder particle size sieving and customized foreign-language labels. Supporting skincare/oral formulation development, interpretation of raw material regulations for global markets and customs clearance document compilation.

II. General Basic Acceptance Indicators for All Grades

1. Glucuronic acid content: ≥42.0% for medical grade; ≥41.5% for high-end cosmetic grade; ≥40.0% for general daily chemical and food grade.

2. Heteroprotein: ≤0.1% for medical and aesthetic grade; ≤0.3% for general daily chemical grade.

3. Moisture content: ≤8.0% for all specifications; ≤5.0% for medical freeze-dried grade. Higher moisture content raises risks of moisture absorption and caking.

4. Ignition residue: ≤0.5% for medical and cosmetic grade; ≤1.0% for general grade.

5. Sensory properties and solubility: Odorless white powder, rapidly soluble in pure water to form transparent viscous solution; caking or yellowing indicates moisture-induced deterioration.

6. Microorganisms: Control of total bacterial count and mold for food/cosmetic grades; absence of all pathogenic bacteria for medical grade.

III. Specialized Control Indicators by Application Scenario

(I) Medical Injection & Ophthalmic Raw Materials (High-End Markets: EU, US, Japan, South Korea)

Comply with USP/EP standards with strict controls on endotoxins, ethanol residues, heavy metals and proteins; sterile production and tightly restricted molecular weight fluctuation ranges.

(II) High-End Medical Aesthetic Cosmetic Raw Materials

Heavy metal and microorganism levels meet EU and Japanese/South Korean cosmetic regulations; stable viscosity without delamination or precipitation after high-low temperature cycling.

(III) Oral Food-Grade Hyaluronic Acid

All indicators comply with food additive standards of target countries; heavy metal and microorganism limits fully compliant.

(IV) Affordable Daily Chemical Raw Materials

Primary controls on glucuronic acid content, moisture and appearance, with cost optimization as the priority.

IV. Cross-Border Supporting Qualifications & Risk Control

(I) Mandatory Export Documentation

Basic documents: Production qualification certificates, ISO22000, GMP, MSDS, batch-specific COAs, full SGS test reports (covering glucuronic acid, protein, solvent residues, heavy metals and microorganisms).

· EU: REACH registration, CPNP notification (cosmetics), EFSA filing (edible HA).

· North America: FDA raw material filing, cGMP documentation.

· Japan & South Korea: Raw material registration with the Ministry of Health, Labour and Welfare. Value-added certifications: HALAL, KOSHER, non-GMO certificates.

(II) Inherent Product Risks

1. Extreme hygroscopicity: Vacuum-sealed packaging is mandatory for marine shipments under high humidity; broken packaging causes rapid water absorption and irreversible caking.

2. Molecular degradation and viscosity loss under high temperature, strong acid or alkali; neutral pH is recommended for finished formulations.

3. Excessive heteroprotein and molecular weight deviation are core barriers to export to high-end cosmetic and pharmaceutical markets in the EU, US, Japan and South Korea; batch testing is compulsory for shipments to these regions.

If you require more professional and in-depth analysis regarding Hyaluronic Acid procurement, please contact HiSiaddi customer service.